Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

This is a Phase 3 study comparing Pfizer investigational PF-08046054/SGN-PDL1V to docetaxel in adults with previously treated PD-L1 positive non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PF-08046054/SGN-PDL1V

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic | Phase 3 | Status: RECRUITING